Recommendations in the Management of Amyotrophic Lateral Sclerosis
DOI:
https://doi.org/10.25759/spmfr.285Keywords:
Amyotrophic Lateral Sclerosis, Rehabilitation, Healthcare Team, Health PlanningAbstract
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease with onset in the adulthood. It involves the upper and lower motor neurons with progressive degeneration of the cells and neurons of the anterior horns of the spinal cord. There is no cure, being always fatal, whereby symptomatic and rehabilitative treatment is vitally important. This review aims to group current knowledge about the diagnosis and treatment of ALS in a systematic, comprehensive and easy way to consult, adapted to the Portuguese reality. We made a literature review focused on the treatment and rehabilitation of amyotrophic lateral sclerosis with emphasis in publications of the last 10 years.
Downloads
References
Andersen P, Abrahams S, Borasio G, Carvalho M, Chioe A, Van Dammef P, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol. 2012; 19: 350–75.
Forsgren L, Almay BG, Holmgren G, Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand. 1983; 68: 20–9.
Alonso A, Logroscino G, Jick SS, Hernan MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16: 745–51. doi: 10.1111/j.1468-1331.2009.02586.x.
Chio,A, Mora, G, Calvo, A, Mazzini, L, Bottacchi E, Mutani R. Epidemiology of ALS in Italy: A 10-year prospective population-based study. Neurology. 2009; 72: 725-31.
Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012. Cochrane Database Syst Rev. 2012;2012:CD001447. doi: 10.1002/14651858.CD001447
Andersen P, Abrahams S, Borasio G, Carvalho M, Chioe A, Van Dammef P, et al. Management of amyotrophic lateral sclerosis. In: Gilhus NE, Barnes MP, Brainin M eds. European Handbook of Neurological Management, 2nd ed.. Chichester: Wiley-Blackwell; 2010. p. 283–310.
Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639-49.
Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009; 4:3.
Xerez DR. Reabilitação na Esclerose Lateral Amiotrófica: revisão da literatura. Acta Fisiátrica São Paulo. 2008;15:182-8.
Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265-7.
Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38-43.
Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. Pract Neurol. 2013;13:153-64. doi: 10.1136/practneurol-2013-000557.
Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 1:293-9.
Carvalho M, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler. 2009; 10: 53–7.
Douglass CP, Kandler RH, Shaw PJ, McDermott CJ. An evaluation of neurophysiological criteria used in the diagnosis of motor neurone disease. J Neurol Neurosurg Psychiatry. 2010; 81: 646–9.
Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011; 70: 79–83.
Okita T, Nodera H, Shibuta Y, Nodera A, Asanuma K, Shimatani Y, et al. Can Awaji ALS criteria provide earlier diagnosis than the revised El Escorial criteria? J Neurol Sci. 2011; 302: 29–32.
Miller RG, Jackson CE, Kasarskis EJ. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218-26. doi: 10.1212/WNL.0b013e3181bc0141.
Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002; 249: 609–15.
Cruz MP. Edaravone (radicava). A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P T . 2018;43:25-8.
Majmudar S, Wu J, Paganoni S. Rehabilitation in amyotrophic lateral sclerosis: why it matters. Muscle Nerve. 2014; 50: 4–13. doi:10.1002/mus.24202.
Paganoni S, Karam C, Joyce N, Bedlack R, Carter GT. Comprehensive rehabilitative care across the spectrum of Amyotrophic Lateral Sclerosis. NeuroRehabilitation.2015;37: 53–68.
Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;31:5:CD005229.
Chen A, Montes J, Mitsumoto H. The Role of Exercise in Amyotrophic Lateral Sclerosis. Phys Med Rehabil Clin N Am. 2008; 19: 545–57.
Almeida JP, Silvestre R, Pinto AC, Carvalho M. Exercise and amyotrophic lateral sclerosis. Neurol Sci. 2012;33:9-15.
Drory VE, Goltsman E, Reznik JG Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001; 91: 133-7.
Bello-Haas VD, Florenc, JM, Kloos AD, Scheirbecker LG, Hayes SM, Pioro EP, et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology. 2007; 68: 2003-7. doi:
1212/01.wnl.0000264418.92308.a4.
Majmudar S, Wu J, Paganoni S. Rehabilitation In Amyotrophic Lateral Sclerosis: Why It Matters. Muscle Nerve. 2014; 50: 4–13. doi:10.1002/mus.24202.
Macpherson CE, Clare C. Pulmonary physical therapy techniques to enhance survival in amyotrophic lateral sclerosis: a systematic review. J Neurol Phys Ther. 2016;40:165-75. doi: 10.1097/NPT.0000000000000136.
Pinto S, Carvalho M. Can inspiratory muscle training increase survival in early-affected amyotrophic lateral sclerosis patients? Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:124-6. doi:
3109/17482968.2012.726227.
Pinto S, Pinto A, de Carvalho M. Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clin Neurophysiol. 2012;123:2454-9. doi: 10.1016/j.clinph.2012.05.012.
Vignola A, Guzzo A, Calvo A, Moglia C, Pessia A, Cavallo E, et al. Anxiety undermines quality of life in ALS patients and caregivers. Eur J Neurol. 2008; 15: 1231–6.
Wicks P, Abrahams S, Masi D, Hejda-Forde S, Leigh PN, Goldstein LH. Prevalence of depression in a 12-month consecutive sample of patients with ALS. Eur J Neurol. 2007; 14: 993–1001.
Elman LB, Siderowf A, Houseman G, Kelley M, McCluskey LF. Venous thrombosis in an ALS population over four years. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 246–9.
Qureshi MM, Cudkowicz ME, Zhang H, Raynor E. Increased incidence of deep venous thrombosis in ALS. Neurology. 2007; 68: 76–7.
Gil J, Funalot B, Verschueren A. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol. 2008; 15: 1245– 51.
Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017. 1:CD011776. doi: 10.1002/14651858.CD011776.pub2.
Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011; 82: 628–34.
Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: a prospective study. Neurology. 2005; 64: 1222–6.
Flaubert JL, Spicer CM, Jette AM, editors. The Promise of Assistive Technology to Enhance Activity and Work Participation. Washington: National Academies Press; 2017.
Fundação PT Soluções Especiais PT [consultado 2018 Junho] Disponível em: http://www.fundacao.telecom.pt [homepage na Internet].
Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005; 65: 586–90.
Panigni F. Psychological wellbeing and quality of life in amyotrophic lateral sclerosis: A review. Int J Psychol. 2013;48:194-205. doi: 10.1080/00207594.2012.691977.
Harris M, Thomas G, Thomas M, Cafarella P, Stocks A, Greig J, McEvoy RD. Supporting wellbeing in motor neurone disease for patients, carers, social networks, and health professionals: A scoping review and synthesis. Palliat Support Care. 2018;16:228-37. doi: 10.1017/S1478951517000700.
Mitsumoto H, Bromberg M, Johnston W, Tandan R, Byock I, Lyon M et al. Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 145–54.
Downloads
Published
How to Cite
Issue
Section
License
Copyright statement
Authors must also submit a copyright statement (as seen below) on article submission.
To the Editor-in-chief of the SPMFR Journal:
The below signed author(s) hereby state that the article
________________________________________ (ref. MFR_________) is
an original unpublished work and all facts stated are a product of the author(s) investigation. This article does not violate any copyright laws or privacy statements. The author(s) also hereby confirm that there is no conflict of interest's issues in this article.
By submitting this article the author(s) agree that after publication all copyrights belong to the SPMFR Journal.
Signed by all authors
Date:
Names (capital letters):
Signatures:
The SPMFR Journal’s contents are follow a Creative Commons licence. After publication the authors can hand out the articles as long as the SPMFR Journal is credited.
